EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Phase II study of neoadjuvant chemotherapy with four cycles of dose‐dense MVAC followed by radical cystectomy in Korean patients with muscle‐invasive or locally advanced urothelial carcinoma of bladder

Kwonoh Park iD, Hyun Jung Lee, Tae Un Kim, Hwaseong Ryu, Yong Kan Ki, Yun Jeong Hong, Jong Kil Nam

Asia-Pacific Journal of Clinical Oncology · 2023

DOI: 10.1111/ajco.13996 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2023. Verfasst von Kwonoh Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Medical Oncology and Hematology, Pusan National University Yangsan Hospital, Pusan National University School of Med…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

While previous retrospective or phase II studies in Western populations showed that dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) as neoadjuvant chemotherapy (NAC) was beneficial, no studies have been reported in Asian populations. This prospective phase II study aimed to evaluate efficacy and safety of ddMVAC in Korean patients with muscle‐invasive bladder cancer (MIBC) or locally advanced urothelial cancer (UC). Materials and Methods Patients with MIBC (cT2–4aN0M0) or locally advanced UC (cTanyN1–3M0) eligible for radical cystectomy (RC) were enrolled prospectively. The participants were treated with four cycles of ddMVAC with pegfilgrastim every 2 weeks. The primary endpoint was pathologic response rate (≤ypT1N0). Secondary endpoints were pathologic complete response (pCR, ypT0N0), relapse‐free survival (RFS), overall survival (OS), and safety.

Results

Among 24 patients enrolled between December 2019 and August 2021, 23 were evaluable (52%, cT2–4aN0; 48%, cTanyN1–3). Eighteen patients (78%) completed four cycles of ddMVAC, while remaining five patients experienced early discontinuation. Dose modification (91%) and dose delay (70%) occurred, and the dose intensity of ddMVAC was 79%. Nineteen patients underwent RC and four patients declined. Of 19 patients who underwent RC, eight patients (42%) achieved ≤ypT1N0. With a median follow‐up of 22.8 months, the median RFS was 13.5 months (95% CI, not yet evaluable) and the median OS was 28.9 months (95% confidence interval, 19.9–37.9).

Conclusion

Our study showed substantial efficacy and safety of ddMVAC, even in patients with locally advanced UC. The ddMVAC still should be a promising option as NAC in Asian patients with UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCarcinoma, Transitional CellHumansUrinary BladderCystectomyNeoadjuvant TherapyRetrospective StudiesProspective StudiesTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsNeoplasm StagingNeoplasm Recurrence, LocalCisplatinMusclesRepublic of KoreaNeoplasm InvasivenessVinblastine

Stichwörter der Autor:innen

dose-dense MVACneoadjuvanturothelial carcinoma

Substanzen

CisplatinVinblastine

Autor:innen und Institutionen

  • Department of Internal Medicine, Medical Oncology and Hematology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, South Korea.
  • Department of Internal Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, South Korea.
  • Department of Pathology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, South Korea.
  • Department of Radiology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, South Korea.
  • Department of Radiation Oncology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, South Korea.
  • Department of Neurology, Uijeongbu St. Mary's Hospital, Catholic University of Korea, Seoul, South Korea.

ORCID-Profile: Kwonoh Park

Förderung

  • Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital
  • National Research Foundation of Korea (NRF)

Zitieren

APA

Park, K., Lee, H. J., Kim, T. U., Ryu, H., Ki, Y. K., Hong, Y. J., & Nam, J. K. (2023). Phase II study of neoadjuvant chemotherapy with four cycles of dose‐dense MVAC followed by radical cystectomy in Korean patients with muscle‐invasive or locally advanced urothelial carcinoma of bladder. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.13996

Vancouver

Park K, Lee HJ, Kim TU, Ryu H, Ki YK, Hong YJ, et al. Phase II study of neoadjuvant chemotherapy with four cycles of dose‐dense MVAC followed by radical cystectomy in Korean patients with muscle‐invasive or locally advanced urothelial carcinoma of bladder. Asia-Pacific Journal of Clinical Oncology. 2023. doi:10.1111/ajco.13996

BibTeX
@article{Park2023,
  author = {Park, Kwonoh and Lee, Hyun Jung and Kim, Tae Un and Ryu, Hwaseong and Ki, Yong Kan and Hong, Yun Jeong and Nam, Jong Kil},
  title = {Phase II study of neoadjuvant chemotherapy with four cycles of dose‐dense MVAC followed by radical cystectomy in Korean patients with muscle‐invasive or locally advanced urothelial carcinoma of bladder},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1111/ajco.13996}
}
Kostenlos starten →